Payment overview · 2025
General Payments
$261.28
12 reported records · 9 companies
Healthcare provider profile · identity verified
Arthur Wayne Pearson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · POTEAU, OK · NPI 1811331754
Verified facts
What the public records show
CMS Open Payments records show Arthur Wayne Pearson, M.D. received $261.28 in general payments during 2025 across 12 reported records.
Lundbeck LLC accounted for 24.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Rexulti, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 208 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 247 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Tresiba by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $64.52 | 24.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.66 | 13.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.08 | 12.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.25 | 11.6% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.34 | 8.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.23 | 7.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.56 | 7.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.55 | 7.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.09 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $222.74 | 11 |
| Education | $38.54 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $97.60 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $35.66 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $30.25 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 171 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 142 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
208 | 59 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
142 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
200 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
171 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
134 | 23 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
247 | 65 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1633 | 318 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1291 | 239 |
| Furosemide | Furosemide | 1158 | 192 |
| Amlodipine Besylate | Amlodipine Besylate | 1086 | 219 |
| Potassium Chloride | Potassium Chloride | 934 | 143 |
| Gabapentin | Gabapentin | 902 | 196 |
| Lisinopril | Lisinopril | 882 | 216 |
| Pantoprazole Sodium | Pantoprazole Sodium | 826 | 184 |
| Metformin Hcl | Metformin Hcl | 763 | 135 |
| Tamsulosin Hcl | Tamsulosin Hcl | 672 | 135 |
| Metoprolol Tartrate | Metoprolol Tartrate | 612 | 119 |
| Trazodone Hcl | Trazodone Hcl | 606 | 115 |
| Eliquis | Apixaban | 586 | 81 |
| Carvedilol | Carvedilol | 562 | 101 |
| Sertraline Hcl | Sertraline Hcl | 552 | 103 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 466 | 119 |
| Omeprazole | Omeprazole | 458 | 137 |
| Losartan Potassium | Losartan Potassium | 421 | 112 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 393 | 119 |
| Simvastatin | Simvastatin | 369 | 55 |
| Mirtazapine | Mirtazapine | 359 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 355 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 346 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 338 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 338 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 333 | 85 |
| Donepezil Hcl | Donepezil Hcl | 322 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 316 | 82 |
| Tramadol Hcl | Tramadol Hcl | 294 | 97 |
| Divalproex Sodium | Divalproex Sodium | 290 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 269 | 56 |
| Allopurinol | Allopurinol | 264 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 261 | 89 |
| Pregabalin | Pregabalin | 259 | 44 |
| Ozempic | Semaglutide | 247 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 237 | 50 |
| Meloxicam | Meloxicam | 234 | 72 |
| Citalopram Hbr | Citalopram Hydrobromide | 233 | 48 |
| Levetiracetam | Levetiracetam | 211 | 24 |
| Farxiga | Dapagliflozin Propanediol | 208 | 59 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 203 | 50 |
| Jardiance | Empagliflozin | 200 | 34 |
| Montelukast Sodium | Montelukast Sodium | 191 | 48 |
| Tresiba Flextouch U-200 | Insulin Degludec | 190 | 47 |
| Memantine Hcl | Memantine Hcl | 189 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 185 | 46 |
| Baclofen | Baclofen | 184 | 35 |
| Oxybutynin Chloride | Oxybutynin Chloride | 184 | 27 |
| Lorazepam | Lorazepam | 183 | 24 |
| Clonazepam | Clonazepam | 177 | 33 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 174 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 173 | 22 |
| Fenofibrate | Fenofibrate | 172 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 172 | 36 |
| Mounjaro | Tirzepatide | 171 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 162 | 28 |
| Xarelto | Rivaroxaban | 149 | 26 |
| Sucralfate | Sucralfate | 146 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 145 | 33 |
| Olanzapine | Olanzapine | 145 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 142 | 28 |
| Trulicity | Dulaglutide | 134 | 23 |
| Alprazolam | Alprazolam | 132 | 24 |
| Ondansetron Odt | Ondansetron | 121 | 56 |
| Buspirone Hcl | Buspirone Hcl | 118 | 29 |
| Finasteride | Finasteride | 118 | 28 |
| Metformin Hcl Er | Metformin Hcl | 118 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 118 | 24 |
| Risperidone | Risperidone | 117 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 117 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 116 | 26 |
| Prednisone | Prednisone | 106 | 53 |
| Amiodarone Hcl | Amiodarone Hcl | 103 | 19 |
| Ranolazine Er | Ranolazine | 103 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 101 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 100 | 64 |
| Promethazine Hcl | Promethazine Hcl | 98 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 25 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 94 | 16 |
| Clonidine Hcl | Clonidine Hcl | 90 | 19 |
| Nystatin | Nystatin | 88 | 43 |
| Topiramate | Topiramate | 88 | 16 |
| Gemtesa | Vibegron | 86 | 21 |
| Venlafaxine Hcl | Venlafaxine Hcl | 83 | 12 |
| Atenolol | Atenolol | 78 | 15 |
| Nitroglycerin | Nitroglycerin | 78 | 50 |
| Myrbetriq | Mirabegron | 76 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 76 | 20 |
| Cefdinir | Cefdinir | 75 | 64 |
| Gemfibrozil | Gemfibrozil | 75 | suppressed |
| Latanoprost | Latanoprost | 75 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 74 | 60 |
| Estradiol | Estradiol | 74 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 74 | 35 |
| Alendronate Sodium | Alendronate Sodium | 73 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 72 | 56 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 71 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 13 |
| Nifedipine Er | Nifedipine | 70 | 12 |
| Diazepam | Diazepam | 69 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 68 | 12 |
| Lovastatin | Lovastatin | 67 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 66 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 66 | suppressed |
| Azithromycin | Azithromycin | 64 | 61 |
| Prazosin Hcl | Prazosin Hcl | 64 | suppressed |
| Spironolactone | Spironolactone | 62 | 22 |
| Albuterol Sulfate | Albuterol Sulfate | 61 | 19 |
| Bupropion Xl | Bupropion Hcl | 61 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 61 | 15 |
| Ezetimibe | Ezetimibe | 61 | 24 |
| Propranolol Hcl | Propranolol Hcl | 61 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 60 | 19 |
| Entresto | Sacubitril/Valsartan | 59 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 58 | suppressed |
| Famotidine | Famotidine | 57 | 25 |
| Glipizide | Glipizide | 57 | 14 |
| Warfarin Sodium | Warfarin Sodium | 57 | 12 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 56 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 55 | 13 |
| Calcium Acetate | Calcium Acetate | 54 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 54 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 17 |
| Celecoxib | Celecoxib | 53 | 12 |
| Tradjenta | Linagliptin | 53 | suppressed |
| Lamotrigine | Lamotrigine | 52 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 51 | 14 |
| Torsemide | Torsemide | 50 | 15 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 16 |
| Aripiprazole | Aripiprazole | 49 | suppressed |
| Mupirocin | Mupirocin | 49 | 37 |
| Methylprednisolone | Methylprednisolone | 48 | 46 |
| Metoclopramide Hcl | Metoclopramide Hcl | 47 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 43 |
| Azelastine Hcl | Azelastine Hcl | 46 | 20 |
| Levofloxacin | Levofloxacin | 46 | 29 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 46 | suppressed |
| Novolog Flexpen | Insulin Aspart | 46 | suppressed |
| Fluconazole | Fluconazole | 45 | 31 |
| Linzess | Linaclotide | 45 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 45 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 36 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 11 |
| Methocarbamol | Methocarbamol | 43 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 41 | 11 |
| Ibuprofen | Ibuprofen | 41 | 17 |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Phenobarbital | Phenobarbital | 40 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 39 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 39 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 38 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 37 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 37 | suppressed |
| Rexulti | Brexpiprazole | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 36 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | 13 |
| Budesonide | Budesonide | 34 | suppressed |
| Digoxin | Digoxin | 34 | suppressed |
| Insulin Degludec | Insulin Degludec | 33 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 31 |
| Benztropine Mesylate | Benztropine Mesylate | 31 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Cilostazol | Cilostazol | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Ertapenem | Ertapenem Sodium | 30 | 18 |
| Naproxen | Naproxen | 30 | suppressed |
| Brilinta | Ticagrelor | 29 | suppressed |
| Belsomra | Suvorexant | 28 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 28 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 28 | suppressed |
| Dutasteride | Dutasteride | 26 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Humalog | Insulin Lispro | 25 | 11 |
| Lactulose | Lactulose | 25 | suppressed |
| Nystop | Nystatin | 25 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Ursodiol | Ursodiol | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 24 | 21 |
| Insulin Aspart Flexpen | Insulin Aspart | 24 | 11 |
| Novolin R | Insulin Regular, Human | 24 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 23 | 17 |
| Clonidine | Clonidine | 23 | suppressed |
| Clotrimazole | Clotrimazole | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Haloperidol | Haloperidol | 23 | suppressed |
| Insulin Lispro | Insulin Lispro | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 23 | 19 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | 12 |
| Tresiba | Insulin Degludec | 23 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 23 | 13 |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Carbamazepine Er | Carbamazepine | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Glucagon Emergency Kit | Glucagon | 22 | 11 |
| Lithium Carbonate | Lithium Carbonate | 22 | suppressed |
| Novolog | Insulin Aspart | 22 | suppressed |
| Cephalexin | Cephalexin | 20 | 18 |
| Colesevelam Hcl | Colesevelam Hcl | 20 | suppressed |
| Humulin R | Insulin Regular, Human | 20 | suppressed |
| Klayesta | Nystatin | 20 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Clozapine | Clozapine | 19 | suppressed |
| Constulose | Lactulose | 19 | suppressed |
| Pentoxifylline | Pentoxifylline | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Tobramycin | Tobramycin | 19 | 16 |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Paliperidone Er | Paliperidone | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Acetic Acid | Acetic Acid | 16 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 15 |
| Cimetidine | Cimetidine | 16 | suppressed |
| Erythromycin | Erythromycin Base | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 15 | suppressed |
| Galantamine Er | Galantamine Hbr | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Austedo | Deutetrabenazine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | 11 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Insulin Aspart | Insulin Aspart | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $261.28 · 12 records | Lundbeck LLC | AIRSUPRA, AREXVY, Dexcom G6 Transmitter, FANAPT, MOUNJARO, REXULTI, TRELEGY ELLIPTA, Wegovy, YUPELRI, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error